Summit Therapeutics Inc. (SMMT) Operating income 2017–2024
Summit Therapeutics Inc. (SMMT) annual operating income history from SEC filings — each fiscal year as reported.
-$226.0MFY2024 · since FY2017: -$28.4M → -$226.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$226.0M | +62.9% |
| FY2023 | -$609.6M | -745.7% |
| FY2022 | -$72.1M | +16.4% |
| FY2021 | -$86.2M | -62.0% |
| FY2020 | -$53.2M | — |
| FY2018 | $5.4M | +119.0% |
| FY2017 | -$28.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SMMT financial trends
SMMT RevenueSMMT Net incomeSMMT Net marginSMMT Gross profitSMMT Gross marginSMMT Operating marginSMMT Operating cash flowSMMT Free cash flowSMMT Capital expendituresSMMT Return on equitySMMT Stock buybacksSMMT Dividends paidSMMT Total assetsSMMT Total liabilitiesSMMT Shareholders’ equitySMMT overview →